ArticleInternational journal of nanomedicine2025
Enhancing the Antidepressant Efficacy of Quercetin via Brain-Targeted Lipid Nanocarriers: Fabrication, Characterization, and Evaluation.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanomedicine for Depression: From Blood-Brain Barrier Delivery to Neuroimmune-Barrier-Plasticity Network Reprogramming.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to develop a quercetin-loaded nanoparticles (QNP) with enhanced brain delivery capacity, which enables efficient delivery of quercetin to target brain regions under the guidance of borneol for the treatment of depression. Methods: We prepared QNP via the thin-film dispersion method and characterized them by particle size, polydispersity index (PDI), zeta potential, morphology, release profile, and stability. Subsequently, a suite of models and assays including hemolysis test, cellular CCK-8 assay, cellular uptake experiment, and lipopolysaccharide (LPS) induced BV2 cell stress model were employed to comprehensively assess the antidepressant activity of QNP. Finally, we validated the in vivo antidepressant effect of QNP using an established depression mouse model. Results: QNP exhibit a spheroidal shape with favorable particle size, PDI, and zeta potential. They have high encapsulation efficiency and exhibit sustained drug release capability. QNP remain stable in serum and saline solution. They maintain stability after 30 days of storage at room temperature. Results from the hemolysis test and cellular CCK-8 assay preliminarily suggested that QNP had a favorable safety profile. Additionally, cellular uptake experiments showed that the uptake rate of QNP by cells was nearly twice that of the quercetin. Assays using corticosterone- and hydrogen peroxide-induced PC12 cell injury models demonstrate that QNP exert a concentration-dependent cytoprotective effect. In the LPS-induced BV2 cell stress model, QNP exhibit superior inhibitory activity against NO and ROS compared with Qu. They also significantly inhibit IL-1β transcription. In vivo studies indicated that, compared with the first-line antidepressant fluoxetine, QNP alleviated depressive-like behaviors more effectively. Conclusion: The lipid nanodrug delivery system QNP exhibit sustained drug release and enhanced cellular uptake. By virtue of safety and improved delivery efficiency, they multidimensionally augment the therapeutic efficacy of antidepressants. This is crucial for translating quercetin from a dietary supplement into a precision antidepressant.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.